Treatment-resistant schizophrenia patients show elevated anterior cingulate cortex glutamate compared to treatment-responsive

Elias Mouchlianitis, Michael A.P. Bloomfield, Vincent Law, Katherine Beck, Sudhakar Selvaraj, Naresh Rasquinha, Adam Waldman, Federico E. Turkheimer, Alice Egerton, James Stone, Oliver D. Howes

Research output: Contribution to journalArticlepeer-review

136 Scopus citations


Introduction: Resistance to antipsychotic treatment is a significant clinical problem in patients with schizophrenia with approximately 1 in 3 showing limited or no response to repeated treatments with antipsychotic medication. The neurobiological basis for treatment resistance is unknown but recent evidence implicates glutamatergic function in the anterior cingulate cortex. We examined glutamate levels of chronically ill treatment-resistant patients directly compared to treatment-responsive patients. Methods: We acquired proton magnetic resonance spectroscopy (1H-MRS) at 3 Tesla from 21 treatment-resistant and 20 treatment-responsive patients. All participants had a DSM-IV diagnosis of schizophrenia. Treatment-resistant patients were classified using the modified Kane criteria. The groups were matched for age, sex, smoking status, and illness duration. Results: Glutamate to creatine ratio levels were higher in treatment-resistant patients (Mean [SD] = 1.57 [0.24]) than in treatment-responsive patients (Mean[SD] = 1.38 [0.23]), (T[35] = 2.34, P =. 025, 2-tailed), with a large effect size of d = 0.76. A model assuming 2 populations showed a 25% improvement in the fit of the Akaike weights (0.55) over a model assuming 1 population (0.44), producing group values almost identical to actual group means. Discussion: Increased anterior cingulate glutamate level is associated with treatment-resistant schizophrenia. This appears to be a stable neurobiological trait of treatment-resistant patients. We discuss possible explanations for glutamatergic dysfunction playing a significant role in resistance to conventional antipsychotic treatments, which are all dopamine-2 receptor blockers. Our findings suggest that glutamatergic treatments may be particularly effective in resistant patients and that 1H-MRS glutamate indices can potentially have clinical use.

Original languageEnglish (US)
Pages (from-to)744-752
Number of pages9
JournalSchizophrenia Bulletin
Issue number3
StatePublished - May 1 2016


  • 1H-MRS
  • NMDA
  • antipsychotics
  • glutamate
  • imaging and schizophrenia
  • neurochemistry
  • psychosis
  • treatmentresistance

ASJC Scopus subject areas

  • Psychiatry and Mental health


Dive into the research topics of 'Treatment-resistant schizophrenia patients show elevated anterior cingulate cortex glutamate compared to treatment-responsive'. Together they form a unique fingerprint.

Cite this